Intriguingly, our targeted investigation indicates that tipifarnib treatment or silencing of the farnesylation substrate PTP4A1 in STK11-mutant lung cancer cells results in inhibition of proliferation as well as impaired tonic interferon signaling. The gene discussed is STK11; the disease is lung carcinoma.